NIPD Genetics, an early-stage Cypriot molecular diagnostics firm, said last week that it has raised €2.5 million (about $3.36 million) and moved into a new facility to support the planned commercialization of its noninvasive prenatal diagnostic test for Down syndrome.
The company, an October 2010 spinoff of the non-profit Cyprus Institute of Neurology and Genetics, developed its test based on the research of CING scientist Philippos Patsalis.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
